(Q38071691)

28 August 2017

1 reference

title

Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma (English)

1 reference

28 August 2017

4

Stephen Holgate

1 reference

28 August 2017

Massimo Caruso

1

1 reference

28 August 2017

Emanuele Crisafulli

series ordinal

2

1 reference

28 August 2017

Shirin Demma

series ordinal

3

1 reference

28 August 2017

Riccardo Polosa

series ordinal

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

393-402

1 reference

An overview of chronic severe asthma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

A national estimate of the economic costs of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Costs of asthma are correlated with severity: a 1-yr prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Asthma severity and medical resource utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

The mechanisms, diagnosis, and management of severe asthma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Severe asthma in adults: what are the important questions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Managing patients with chronic severe asthma: rise to the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Difficult to treat asthma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Recommendation for optimal management of severe refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Harnessing regulatory T cells to suppress asthma: from potential to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Xolair in asthma therapy: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Off-label use of omalizumab in non-asthma conditions: new opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Interleukin-13: central mediator of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

IL-13 receptors and signaling pathways: An evolving web

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Crosstalk between TNF and glucocorticoid receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

OX40-OX40L interactions: a promising therapeutic target for allergic diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.743989

10.1517/14712598.2013.743989

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference